Modeling HCV kinetics under therapy using PK and PD information

Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):321-32. doi: 10.1517/17425250902787616.

Abstract

Background: Mathematical models have proven helpful in analyzing the virological response to antiviral therapy in hepatitis C virus (HCV) infected subjects.

Objective: To summarize the uses and limitations of different models for analyzing HCV kinetic data under pegylated IFN therapy.

Methods: We formulate mathematical models and fit them by nonlinear least square regression to patient data to estimate model parameters. We compare the goodness of fit and parameter values estimated by different models statistically.

Results/conclusion: The best model for parameter estimation depends on the availability and the quality of data as well as the therapy used. We also discuss the mathematical models that will be needed to analyze HCV kinetic data from clinical trials with new antiviral drugs.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use*
  • Hepacivirus / drug effects
  • Hepacivirus / genetics
  • Hepatitis C / drug therapy*
  • Hepatitis C / genetics
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / pharmacokinetics
  • Interferon-alpha / therapeutic use
  • Least-Squares Analysis
  • Models, Biological*
  • Polyethylene Glycols / pharmacokinetics
  • Polyethylene Glycols / therapeutic use
  • RNA, Viral / drug effects
  • RNA, Viral / metabolism
  • Recombinant Proteins

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2b
  • peginterferon alfa-2a